Adialante is building diagnostic-grade MRI in a mobile system for outpatient clinics. The company describes its product as a mobile, affordable imaging stack and a mobile MRI clinic on wheels. Its site says the team has two issued U.S. patents and is backed by Y Combinator.
Adialante specializes in developing next-generation MRI systems that utilize adiabatic radiofrequency pulses. Their main product offerings focus on improving image quality and reducing scan times, particularly for cancer screening, with an emphasis on prostate cancer.
Key features of their technology include:
The company was founded in 2023 and is led by a team of PhDs in engineering and medical imaging. They have received a $1.18 million NSF SBIR Phase II award to further commercialize their technology, indicating strong backing and potential for growth in the medical imaging field.